Serum Level of Soluble Receptor for Advanced Glycation End Products in Acute Coronary Syndrome and Chronic Stable Angina Patients

Authors

  • Fatin Najiah Mohd Idrus School of Health Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
  • Siew Wai Fong School of Health Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
  • Chee Hock Hoe Faculty of Veterinary Medicine, Universiti Malaysia Kelantan, Pengkalan Chepa, 16100 Kota Bharu, Kelantan, Malaysia
  • Zurkurnai Yusof School of Medical Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
  • Get Bee Yvonne-Tee School of Health Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia

Keywords:

Acute coronary syndrome, biomarker, cardiovascular disease, chronic stable angina, PIGF, sRAGE

Abstract

Acute coronary syndrome (ACS) and chronic stable angina (CSA) have different pathophysiological features and prognoses. Hence, a biomarker that can discriminate between ACS and CSA is crucial. Soluble receptor for advanced glycation end product (sRAGE) involved in vascular inflammation shows potential as the emerging diagnostic marker of ACS. Thus, this research examined the difference in serum level of sRAGE in ACS and CSA patients and investigated the association between sRAGE and plaque instability biomarkers like placental growth factor (PIGF). The serum levels of sRAGE and plaque instability biomarkers were measured from 13 ACS [47 years (26)] and 19 CSA patients [51 years (26)] using enzyme-linked immunoassay. The association between serum level of sRAGE and plaque instability biomarkers was determined by a correlation study. Serum level of sRAGE and PIGF were significantly higher in ACS [sRAGE: 3541 pg/mL (2153.8 pg/mL), p<0.000], [PIGF: 51.91 (31.94) pg/mL, p=0.001] compared to CSA patients [sRAGE: 1268 (1510) pg/mL], [PIGF: 17.28 (22.41) pg/mL]. Binomial logistic regression analysis revealed sRAGE and PIGF as possible predictors of ACS, p<0.05. The serum level of sRAGE was higher in ACS patients and could be the potential dual-biomarker with PIGF in cardiovascular disease (CVD) patients.

References

Agewall S. Acute and stable coronary heart disease: different risk factors. Eur Heart J. 2008 Jul 10;29(16):1927–9.

WHO. Cardiovascular disease. 2018.

Seong AC, Chb MB, Kok C, John M, Cth F. A Review of Coronary Artery Disease Research in Malaysia. 2016;71:42–57.

Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes. Part III: Biomarkers of oxidative stress and angiogenic growth factors. Circulation. 2006;113(8):289–92.

Jensen LJN, Flyvbjerg A, Bjerre M. Soluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary Syndrome. Biomed Res Int. 2015;2015.

Kajikawa M, Nakashima A, Fujimura N, Maruhashi T, Iwamoto Y, Iwamoto A, et al. Ratio of serum levels of ages to soluble form of RAGE is a predictor of endothelial function. Diabetes Care. 2015;

Lindsey JB, Cipollone F, Abdullah SM, McGuire DK. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diab Vasc Dis Res. 2009;6(1):7–14.

Villegas-Rodríguez ME, Uribarri J, Solorio-Meza SE, Fajardo-Araujo ME, Cai W, Torres-Graciano S, et al. The AGE-RAGE Axis and Its Relationship to Markers of Cardiovascular Disease in Newly Diagnosed Diabetic Patients. PLoS One. 2016;11(7).

Assiri AMA, Kamel HFM, ALrefai AA. Critical Appraisal of Advanced Glycation End Products ( AGEs ) and Circulating Soluble Receptors for Advanced Glycation End Products ( sRAGE ) as a Predictive Biomarkers for Cardiovascular Disease in Hemodialysis Patients. Med Sci. 2018;6(38):1–13.

Brinkley TE, Leng X, Nicklas BJ, Kritchevsky SB, Ding J, Kitzman DW, et al. Racial Differences in Circulating Levels of the Soluble Receptor for Advanced Glycation Endproducts in Middle-Aged and Older Adults Tina. Metabolism. 2017;70:98–106.

Grauen H, Yndigegn T, Marinkovic G, Grufman H, Mares R, Nilsson J, et al. The soluble receptor for advanced glycation end-products ( sRAGE ) has a dual phase-dependent association with residual cardiovascular risk after an acute coronary event. Atherosclerosis. 2019;287:16–23.

Mahajan N, Dhawan V. Receptor for advanced glycation end products (RAGE) in vascular and inflammatory diseases. Int J Cardiol. 2013;168(3):1788–94.

Cai XY, Lu L, Wang YN, Jin C, Zhang RY, Zhang Q, et al. Association of increased S100B, S100A6 and S100P in serum levels with acute coronary syndrome and also with the severity of myocardial infarction in cardiac tissue of rat models with ischemia-reperfusion injury. Atherosclerosis. 2011;217(2):536–42.

Falcone C, Emanuele E, D’Angelo A, Buzzi MP, Belvito C, Cuccia M, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 2005;25(5):1032–7.

Yan XX, Lu L, Peng WH, Wang LJ, Zhang Q, Zhang RY, et al. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis. 2009;205(2):544–8.

Loomis SJ, Chen Y, Sacks DB, Christenson ES, Robert H, Rebholz CM, et al. Cross-sectional Analysis of AGE-CML, sRAGE, and esRAGE with Diabetes and Cardiometabolic Risk Factors in a Community- Based Cohort Stephanie. Clin Chem. 2017;63(5):980–9.

Reichert S, Triebert U, Navarrete A, Hofmann B, Schaller H, Schlitt A, et al. Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease. Atherosclerosis. 2017;266:234–9.

Boudoulas KD, Triposciadis F, Geleris P, Boudoulas H. Coronary Atherosclerosis: Pathophysiologic Basis for Diagnosis and Management. Prog Cardiovasc Dis. 2016;58(6):676–92.

Basta, G., Turco, S.D., Marchi, F., Navarra, T., Battaglia, D., Mercuri, A., Mazzone A. & Berti S. Elevated soluble receptor for advanced glycation end product levels in patient with acute coronary syndrome and positive cardiac troponin I. Coron Artery Dis. 2011;

Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008;22(10):3716–27.

Zheng H, Li Y, Xie N, Huang JL, Xu HF, Luo M. Decreased levels of soluble receptor for advanced glycation end-products in aortic valve calcification patients. Genet Mol Res. 2015;14(2):3775–83.

Bower JK, Pankow JS, Lazo M, Christenson E, Hoogeveen RC, Ballantyne CM, et al. Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE). Clin Biochem. 2014;47(1–2):132–4.

Falcone C, Bozzini S, Guasti L, D’Angelo A, Capettini AC, Paganini EM, et al. Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease. ScientificWorldJournal. 2013;2013:584504.

Mulrennan S, Baltic S, Aggarwal S, Wood J, Miranda A, Frost F, et al. The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes. Sci Rep. 2015;5:8931.

Geroldi D, Falcone C, Emanuele E, Angelo AD, Calcagnino M, Buzzi MP, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. 2005;1725–9.

Yoon S, Park S, Park C, Chang W, Cho D, Ko Y, et al. Association of soluble receptor for advanced glycation end-product with increasing central aortic stiffness in hypertensive patients. Pahophysiology Nat Hist. 2012;23:85–90.

Fong SW, Few LL, See Too WC, Khoo BY, Nik Ibrahim NNI, Yahaya SA, et al. Systemic and coronary levels of CRP, MPO, sCD40L and PlGF in patients with coronary artery disease. BMC Res Notes. 2015;8:679.

Wannamethee SG, Welsh P, Papacosta O, Ellins EA, Halcox JPJ, Whincup PH, et al. Circulating soluble receptor for advanced glycation end product : Cross-sectional associations with cardiac markers and subclinical vascular disease in older men with and without diabetes. Atherosclerosis. 2017;264:36–43.

Prasad K. Low Levels of Serum Soluble Receptors for AGEs, biomarkers for disease state, myth or reality. Int J Angiol. 2014;23(1):11–16.

Lenderink T, Heeschen C, Fichtlscherer S, Dimmeler S, Hamm CW, Zeiher AM, et al. Elevated Placental Growth Factor Levels Are Associated With Adverse Outcomes at Four-Year Follow-Up in Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2006;47(2):307–11.

Heeschen C, Dimmeler S, Fichtlscherer S, Hamm CW, Berger J, Simoons ML, et al. Prognostic Value of Placental Growth Factor in Patients With Acute Chest Pain. JAMA. 2004 Jan 28;291(4):435–41.

Lindahl B. Are there really biomarkers of vulnerable plaque? Clin Chem. 2012;58(1):151–3.

Ramachandra CJA, Ja KPMM, Chua J, Cong S, Shim W, Hausenloy DJ. Myeloperoxidase As a Multifaceted Target for Cardiovascular Protection. Antioxidants Redox Signal. 2020;32(15):1135–49.

Govindarajan S, Raghavan VMM, Rao ACV. Plasma myeloperoxidase and total sialic acid as prognostic indicators in acute coronary syndrome. J Clin Diagnostic Res. 2016;10(8):BC09-BC13.

Liu C, Xie G, Huang W, Yang Y, Li P, Tu Z. Elevated serum myeloperoxidase activities are significantly associated with the prevalence of ACS and high LDL-C levels in CHD patients. J Atheroscler Thromb. 2012;19(5):435–43.

Pusuroglu H, Akgul O, Erturk M, Uyarel H, Bulut U, Akkaya E, et al. Predictive value of elevated soluble CD40 ligand in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Coron Artery Dis. 2014;25(7):558–64.

Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC. Soluble CD40 ligand:interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction. Thromb Res. 2007;121(3):293–9.

Gremmel T, Frelinger AL, Michelson AD. Soluble CD40 ligand in aspirin-treated patients undergoing cardiac catheterization. PLoS One. 2015;10(8):1–16.

Mehta R, Bassand J, Chrolavicius S, Diaz R, Eikelboom JW, Health H, et al. Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. N Engl J Med. 2010;363(16):1585–1585.

Rondina MT, Lappe JM, Carlquist JF, Muhlestein JB, Kolek MJ, Horne BD, et al. Soluble CD40 Ligand as a Predictor of Coronary Artery Disease and Long-Term Clinical Outcomes in Stable Patients Undergoing Coronary Angiography. Cardiology. 2008;109(3):196–201.

Downloads

Published

2023-02-17

Issue

Vol. 8 No. 1 (2023): JUNE 2023

Section

Journal of Biomedical and Clinical Sciences

License

JBCS Publication Ethics

JBCS is committed to ensure the publication process follows specific academic ethics. Hence, Authors, Reviewers and Editors are required to conform to standards of ethical guidelines.

Authors
Authors should discuss objectively the significance of research work, technical detail and relevant references to enable others to replicate the experiments. JBCS do not accept fraudulent or inaccurate statements that may constitute towards unethical conduct.

Authors should ensure the originality of their works. In cases where the work and/or words of others have been used, appropriate acknowledgements should be made. JBCS do not accept plagiarism in all forms that constitute towards unethical publishing of an article.

This includes simultaneous submission of the same manuscript to more than one journal. Corresponding author is responsible for the full consensus of all co-authors in approving the final version of the paper and its submission for publication.

Reviewers
Reviewers of JBCS treat manuscripts received for review as confidential documents. Therefore, Reviewers must ensure the confidentiality and should not use privileged information and/or ideas obtained through peer review for personal advantage.

Reviews should be conducted based on academic merit and observations should be formulated clearly with supporting arguments. In cases where selected Reviewer feels unqualified to review a manuscript, Reviewer should notify the editor and excuse himself from the review process in TWO (2) weeks time from the review offer is made.

In any reasonable circumstances, Reviewers should not consider to evaluate manuscripts if they have conflicts of interest (i.e: competitive, collaborative and/or other connections with any of the authors, companies, or institutions affiliated to the papers).

Editors
Editors should evaluate manuscripts exclusively based on their academic merit. JBCS strictly do not allow editors to use unpublished information of authors  without the written consent of the author. Editors are required to take appropriate responsive actions if ethical complaints have been presented concerning a submitted manuscript or published paper.

CONFLICT OF INTEREST

Journal of Biomedical and Clinical Sciences requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a ‘competing interests section at the end of the manuscript listing all competing interests (financial and non-financial). Where authors have no competing interests, the statement should read ,The authors have declared that no competing interests exist. Editors may ask for further information relating to competing interests.

Editors and reviewers are also required to declare any competing interests and will be excluded from the peer review process if a competing interest exists. Competing interests may be financial or non-financial. A competing interest exists when the authors interpretation of data or presentation of information may be influenced by their personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment if they were to become public after the publication of the article.

HUMAN AND ANIMAL RIGHTS

All research must have been carried out within an appropriate ethical framework. If there is suspicion that work has not taken place within an appropriate ethical framework, Editors will follow the Misconduct policy and may reject the manuscript, and/or contact the author(s) institution or ethics committee. On rare occasions, if the Editor has serious concerns about the ethics of a study, the manuscript may be rejected on ethical grounds, even if approval from an ethics committee has been obtained.

Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. Further information and documentation to support this should be made available to Editors on request.

Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. The Basel Declaration outlines fundamental principles to adhere to when conducting research in animals and the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines.

A statement detailing compliance with relevant guidelines (e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or ethical approval (including the name of the ethics committee and the reference number where appropriate) must be included in the manuscript. The Editor will take account of animal welfare issues and reserves the right to reject a manuscript, especially if the research involves protocols that are inconsistent with commonly accepted norms of animal research. In rare cases, Editors may contact the ethics committee for further information.

INFORMED CONSENT

For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear in the manuscript, this includes to all manuscripts that include details, images, or videos relating to individual participants.

DATA SHARING POLICY

JBCS strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files, in machine-readable format (such as spreadsheets rather than PDFs) whenever possible

Authors who do not wish to share their data must state that data will not be shared, and give the reason.

COPYRIGHT NOTICE

The JBCS retains the copyright of published manuscripts under the terms of the Copyright Transfer Agreement. However, the journal permits unrestricted use, distribution, and reproduction in any medium, provided permission to reuse, distribute and reproduce is obtained from the Journal's Editor and the original work is properly cited.

While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Copyright (c) 2023 Journal of Biomedical and Clinical Sciences (JBCS)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.